GSK
GSK
Performance
About GSK
GSK is a focused biopharma company that advances science, technology and talent to address disease worldwide. The company concentrates its research and development in four therapeutic areas—respiratory, immunology and inflammation; oncology; HIV; and infectious diseases—aiming to improve health outcomes for billions of people. Located globally and headquartered in the United Kingdom, GSK emphasizes responsible access, patient safety, and collaboration with partners to translate scientific discoveries into medicines for patients.
Recent News
GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma
Will Pfizer’s Lyme Disease Gamble Pay Off or Set the Space Back?
First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More
FTSE 100 Holds Near‑Flat as UK Investors Await US‑Iran Peace Talks
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
Be Creative, Not A Cowboy: Attorneys Talk Litigation Collaboration Pitfalls
GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial
Pharma and Biotech Layoffs 2026 Watch
GSK Returns Rights to Wave's RNA Editing Program for AATD
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability
JPM26: Filling C-Suites, Union Square—And Elevators—With Pink
Gepotidacin
The New Mixed-Use Must: Data Centres
Sunshine Biopharma Inc (SBFM) Q4 2025 Earnings Call Transcript
STAT+: GSK Picks up Pulmonary Hypertension Drug with 35Pharma Acquisition
GSK’s RSV Vaccine Approved in Europe
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
9 Companies Hiring Now in Pennsylvania
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis
GSK Makes $2.2B Deal for RAPT and Its Food Allergy Candidate
GSK, Noetik Sign Cancer Deal on AI Virtual Cell Models
China Clears Mepolizumab for COPD
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
'Skinny' Generic Vascepa Label Case Reaches US Supreme Court
Tahoe, Arc Institute, and Biohub Join Forces on Massive Virtual Cell Dataset
The New Gold Rush in Brain Science
2025 Novel Large Molecule FDA Drug Approvals
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
FDA Updates Sotrovimab Emergency Use Authorization
Lynavoy (Linerixibat) Wins FDA Approval for Rare Liver Disease After Alfasigma-GSK Licensing Deal
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
GSK Reaches $2.2bn Deal to Buy Food Allergy Biotech RAPT
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines
One Doctor Helped Kickstart US Nuclear Medicine’s New Wave. Now He’s Refining It.
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
Pfizer to Depart GSK's ViiV as Shionogi Doubles Its Stake
Pharma Bets Big on AI Platforms with Flurry of New Year Deals
The US FDA New Drug Approvals in March 2026
GSK Plans Five Phase 3 Studies for Gynecological Cancer ADC From Hansoh
MGNX Restarts LINNET Gene‑Therapy Trial as GSK Wins China Nod and NBIX Acquires SLNO
Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Zoliflodacin (ETX-0914)
Nativeads.ai Brings Generative AI to Power the Future of Dynamic Advertising
GSK Delivers in New CEO Miels' First Financial Update
